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following hemodialysis [9] have also been described. 
Recently, Auerbach et a1 reported an outbreak of 
pseudoinfection with 7: paurometabola, due to culture 
contamination in the laboratory [lo]. T inchonensis was 
isolated from blood cultures of a patient who had 
ingested hydrochloric acid [I I]. To our knowledge, we 
give here the first report that clearly demonstrates the 
pathogenicity of T pulmonis. Interesting in these latter 
cases of bacteremia, and similar to our case report, is 
the absence of tunnel or exit-site inflammation and the 
persistence of fever and positive blood culture despite 
adequate antibiotic therapy until the catheter was 
removed. Moreover, catheter tip cultures implicated 
the catheter as source of infection in all cases, while 
catheter removal resulted in rapid clinical recovery and 
sterilization of blood cultures. Hence, Tsukarnurella sp. 
bacteremia might be, despite its Gram-positive nature, 
an indication for early catheter removal. 
J Maertens,' I? Wattiau,2j. Irevh~egen,~ 
M. Boogaerts,' L. H r b i ~ t , ~  G. Wauters4 
'Department of Internal Medicine, 
Haernatology, 
University Hospitals Leuven, 
Leuven, Belgium; 
2Microbial Pathogenesis Unit, 
University Louvain, Brussels, Belgium; 
3Department of Microbiology, 
Bacteriology, 
University Hospitals Leuven, 
Leuven, Belgium; 
4Department of Microbiology, 
University Hospitals Louvain, 
Brussels, Belgium 
Accepted 2 August 1997 
References 
1. Minnikin DE, Hutchinson IG, Galdcott AB, Goodfellow 
M. Thin layer chromatography of methanolysate of mycolic 
acid containing bacteria. J Chromatogr 1980; 188: 211-25. 
2. Yassin AF, Rainey FA, Brzezinka H, et a]. Tsukamurella 
pulmonis sp. nov. Int J Syst Bacteriol 1996; 46: 429-36. 
3. Collins MD, Smida J, Dorsch M, Stachebrandt E. 
Tsukamurella gen. nov. harboring Corynebacterilrm pauro- 
metabolum and Rhodococcus aurantiacus. Int J Syst Bacteriol 
4. Tsukamura M, Kawakami K. Lung infection caused by 
Gordona aurantiaca (Rhodococcus aurantiacus). J Clin Microbiol 
5. Tsukamura M, Hikosako K, Nishimura K, Hara S. Severe 
progressive subcutaneous abscesses and necrotizing teno- 
synovitis caused by Rhodococcus aurantiacus. J Clin Microbiol 
6. Prinz G, Ban E, Fekete S, Szabo 2. Meningitis caused by 
Gordona aurantiaca (Rhodococcus aurantiacus). J Clin Microbiol 
1988; 38: 385-91. 
1982; 16: 604-7. 
1988; 26: 201-5. 
1985; 22: 472-4. 
7. Casella P, Tommasi A, Tortorano AM. Peritonite da Gordona 
aurantiaca (Rhodococcus aurantiacus) in ddisi  peritoneale 
ambulatorie continua. Microbiol Med 1987; 2: 47-8. 
8. Shapiro CL, Haft RF, Gantz MM, et al. TsukamureIla 
paurometabolum: a novel pathogen causing catheter-related 
bacteraemia in patients with cancer. Clin Infect Dis 1992; 
9. Jones RS, Fekete T, Truant AL, Satishchandran V. Persistent 
bacteremia due to Tsukamurella paurometabolurn in a patient 
undergoing hemodialysis: case report and review. Clin Infect 
Dis 1994; 18: 830-2. 
10. Auerbach SB, McNeil MM, Brown JM, Lasker BA, 
Janvis WR. Outbreak of pseudoinfection with Tsukamurella 
paurometabolum traced to laboratory contamination: eficacy 
of joint epidemiological and laboratory investigation. CIin 
Infect Dis 1992; 14: 1015-22. 
11. Yassin AF, Rainey FA, Brzezinka H, et al. Tsukamurella 
inchonensis sp. nov. Int J Syst Bacteriol 1995; 45: 522-7. 
14: 200-3. 
Prevalence of stably derepressed class I P-lactamase in 
multiresistant clinical isolates of Enrerobacrer cloacae in 
two Hungarian hospitals 
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The clinical use of the new extended-spectrum 
cephalosporins was rapidly followed by the emergence 
of resistance to these antibiotics in several species, 
including Enterobacter cloacae. Therapeutic failures 
associated with the in vivo selection of stably 
derepressed mutants with permanent hyperproduction 
of the chromosomally encoded class I p-lactamases have 
been described for these strains [1,2]. Resistance to new 
extended-spectrum cephalosporins and other clinically 
important antibiotics in isolates of E. cloacae is 
increasing throughout the world. Resistance to 
cefotaxime, ceftazidime and ceftriaxone has been found 
in 68% of the strains in Greece [3]. However, the 
prevalence of resistance may vary among different 
geographical locations. It has been reported that 
resistance to extended-spectrum cephalosporins in 
E. cloacae is most prevalent in the southern part of 
Europe and Belgium [4], while only 5% of 233 isolates 
from a community hospital in the USA proved to be 
resistant to third-generation cephalosporins [5]. In 
addition to p-lactam resistance, a high number ofstrains 
have been observed with resistance to aminoglycosides 
as well [3]. 
We have evaluated the prevalence of resistance of 
p-lactams, aminoglycosides and quinolones in 82 
E. cloacae strains isolated from patients with severe 
infections in two hospitals in Hungary from January to 
August 1995. The origin ofthese strains was urine (32), 
wound samples (27), tracheal aspirates (lo), blood 
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cultures (six), sputum (three) and bile specimens (four). 
Antibiotic susceptibility testing was carried out by the 
disk diffusion test on MueUer-Hinton agar with 21 
antibiotics (Table I); the NCCLS guidelines were used 
for the evaluation [6]. The MICs of four third- 
generation cephalosporins (cefoperazone, cefotaxime, 
ceftriaxone and ceftazidime), four aminoglycosides 
(gentamicin, tobramycin, netilmicin and amikacin) and 
two quinolones (ofloxacin and ciprofloxacin) were also 
tested for selected strains, by the microbroth dilution 
method according to the NCCLS guidelines [6], and 
the B-lactamase activity of the strains was measured 
from the ultrasound-treated cell supernatants after 18 h 
of incubation (Table 2). Sixty-three isolates (77%) 
proved to be sensitive to imipenem but resistant to 
practically all other p-lactam antibiotics. The MICs for 
these strains of all four third-generation cephalosporins 
tested were 232 pg/mL, except for ceftazidime, to 
which six strains (7%) showed only decreased 
susceptibility (16 pg/mL). The MICs of cefuroxime, 
cefamandole and cefoxitin were uniformly high 
(2256 pg/nL) for each strain in this group. Nineteen 
strains (23%) were resistant to cefoxitin but sensitive or 
moderately sensitive to most other p-lactam antibiotics. 
Sixteen strains (19%) were inducible in liquid cultures 
with cefoxitin and imipenem as well as in the disk 
approximation test, where cefoxitin and imipenem 
disks were used as inducers and cefuroxime, 
cefotaxime, ceftriaxone and ceftazidime as indicator 
disks. In this group the ranges of the MICs of the four 
third-generation cephalosporins were 0.25-1 pg/mL, 
while those of cefuroxime and cefamandole were 
8-256 pg/mL, and the MIC of cefoxitin was 
2256 pg/mL. For three strains [3,4,7] (4%) the 
MICs of the third-generation cephalosporins were 
Table 1 In vitro activity of antimicrobial agents against 
Enterobacter cloacae strains 82 
Antimicrobial agents 
Percentage of 
resistant isolates 
AmpiciJlin 
Ampicillin/sulbactam 
Amoxicillin/clavulanate 
Carbenicillin 
Azlocillin 
Mezlocillin 
Cefamandole 
Cefuroxime 
Cefoxitin 
Cefoperazone 
Ceftazidime 
Ceftriaxone 
Cefotaxime 
Imipenem 
Gentamicin 
Tobramycin 
Netilmicin 
Amikacin 
Ciprofloxacin 
Pefloxacin 
Ofloxacin 
Chloramphenicol 
Trimethoprimsulfamethoxazole 
100 
100 
100 
81 
93 
90 
97 
95 
100 
77 
70 
75 
68 
0 
41 
41 
24 
1 
5 
13 
9 
3s 
15 
Table 2 MICs of different antibiotics and P-lactamase activity of selected Enterobacter cloacae strains 
6-Lacramase 
MIC ( pg/mL) activity 
Strain W/me 
- 
no. CXM CFX CTX C R O  CAZ 
, -  
CFP GEN TOB NET AM1 CIP OFL ofuroteini 
3 256 
4 256 
7 8 
10 16 
14 16 
21 8 
29 32 
1 1  > 256 
19 >256 
32 >256 
40 1 2 5 6  
5.8 > 256 
80 >256 
86 >256 
16 >256 
22 >256 
16 
16 
16 
> 256 
> 256 
> 256 
> 256 
> 256 
> 256 
> 256 
> 256 
> 256 
> 256 
> 256 
> 256 
> 256 
0.5 
0.5 
0.25 
0.5 
0.5 
0.5 
0.5 
64 
32 
32 
128 
256 
256 
256 
256 
256 
0.5 0.12 
0.5 0.12 
0.25 0.25 
0.25 0.5 
0.5 1 
0.5 1 
0.5 0.5 
64 32 
64 32 
32 32 
128 32 
256 32 
256 64 
256 32 
256 128 
256 128 
2 
1 
0.5 
0.25 
0.5 
1 
1 
64 
64 
32 
128 
256 
256 
256 
256 
256 
1 1 
0.5 1 
0.5 0.5 
0.5 0.5 
1 1 
0.5 0.5. 
0.5 0.5 
16 16 
32 16 
128 128 
128 128 
64 32 
32 32 
64 16 
128 64 
64 64 
0.5 
0.5 
0.25 
0.25 
0.25 
0.5 
0.25 
32 
64 
64 
32 
32 
32 
64 
64 
32 
0.5 0.12 0.12 
0.25 0.12 0.12 
0.5 0.12 0.12 
0.25 0.06 0.12 
0.25 0.06 0.12 
0.5 0.12 0.12 
0.5 0.12 0.5 
0.25 1 
1 0.25 1 
1 4 8 
0.5 0.5 16 
1 0.25 16 
1 4 8 
1 0.25 8 
0.5 4 16 
0.5 4 16 
16 
0 
0 
0 
8 
0 
0 
19 
2200 
1261 
1537 
1349 
1986 
1674 
1793 
1234 
3256 
CXM, cefuroxlme; CFX. cefoxtin; CTX, cefotaxime; CRO, ceftriaxone; CAZ. ceftazidime; CFP. cefoperazone; GEN, gentamicin; 
TOB, tobramycin; NET, netdmicin; AMI, amikacin; CIP, ciprofloxacin; OFL, ofloxacin. 
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0.12-2 pg/mL, of cefuroxime 8 pg/mL and 
256 pg/mL, and of cefoxitin 16 pg/mL.. Based on low- 
level resistance to cefoxitin and no detectable p- 
lactamase in the quantitative p-lactamase test, these 
strains were considered to be basal p-lactamase 
producers. On the basis of plasmid analysis, among the 
16 selected strains only five harbored a low-molecular- 
weight plasmid. 
A high frequency of aminoglycoside resistance was 
also observed among these 82 E. cloacae strains. 
Thirteen of the 82 strains (16%) were resistant to 
gentamicin and tobramycin, and 20 (24%) were 
resistant to gentamicin, tobramycin and netilmicin. 
One isolate displayed resistance to all four 
aminoglycosides tested. Aminoglycoside resistance was 
observed more frequently among strains exhibiting 
resistance to all third-generation cephalosporins (34 
strains out of 63; 54%). None of the strains fully 
susceptible to third-generation cephalosporins showed 
resistance to aminoglycosides. In our study, 77% of the 
82 E. cloacae strains were demonstrated to be resistant 
to a wide range of p-lactams due to the very high p- 
lactamase production (21234 U/mg) determined by 
the nitrocefin quantitative p-lactamase test. The 
resistance rates of quinolones were very low (5-13%). 
Thirty-eight percent of the strains were resistant 
to chloramphenicol and 15% to trimethoprim- 
sulfamethoxazole. 
All strains that were sensitive to all third-generation 
cephalosporins proved to be susceptible to carbenicillin 
as well; this is a therapeutic option because carbenicillin 
does not select stably derepressed mutants as third- 
generation cephalosporins do. The risk of the selection 
of pre-existing resistant mutants during p-lactam 
therapy of infections caused by E. cloacae is much more 
significant if extended-spectrum cephalosporins are 
used than with aminoglycosides or with other types of 
(3-lactams [7], since third-generation cephalosporins 
kill P-lactamase-inducible cells, but allow survival and 
overgrowth of derepressed mutants [8]. Probably, this 
was the situation in the two hospitals in Hungary, 
where the overuse of the second- and third-generation 
cephalosporins during recent years may have been 
responsible for the selection of stably derepressed 
mutants of class I P-lactamase-producing E. cloacae 
strains. High-risk organisms for the production of 
inducible p-lactamase can readily be recognized in 
clinical microbiological laboratories by accurate 
identification to the species level, which should be 
followed by a strict antibiotic policy during the 
treatment of infections caused by them. Because of the 
risk of the further selection of derepressed mutants, the 
use of extended-spectrum cephalosporins in infections 
caused by P-lactamase-inducible organisms such as 
E. cloacae should be discouraged [8]. 
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